Mustang Bio Inc (MBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mustang Bio Inc (MBIO) has a cash flow conversion efficiency ratio of -0.117x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.01 Million) by net assets ($8.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mustang Bio Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Mustang Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Mustang Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mustang Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mustang Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mittal Life Style Limited
NSE:MITTAL
|
0.102x |
|
Wyncoast Industrial Park Public Company Limited
BK:WIN
|
-0.013x |
|
Hapbee Technologies Inc
V:HAPB
|
0.329x |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
N/A |
|
Quest PharmaTech Inc
V:QPT
|
-0.002x |
|
Conferize A/S
CO:CONFRZ
|
-0.072x |
|
Samchai Steel Industries Public Company Limited
BK:SAM
|
-0.061x |
|
Intercont (Cayman) Limited Ordinary shares
NASDAQ:NCT
|
N/A |
Annual Cash Flow Conversion Efficiency for Mustang Bio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Mustang Bio Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Mustang Bio Inc (MBIO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.53 Million | $-5.26 Million | -0.552x | -118.75% |
| 2024-12-31 | $-3.87 Million | $-11.41 Million | 2.946x | +100.73% |
| 2023-12-31 | $123.00K | $-49.48 Million | -402.252x | -28506.97% |
| 2022-12-31 | $46.27 Million | $-65.07 Million | -1.406x | -194.50% |
| 2021-12-31 | $112.40 Million | $-53.67 Million | -0.477x | -25.94% |
| 2020-12-31 | $98.44 Million | $-37.32 Million | -0.379x | +41.69% |
| 2019-12-31 | $51.65 Million | $-33.58 Million | -0.650x | -22.96% |
| 2018-12-31 | $36.40 Million | $-19.24 Million | -0.529x | -144.33% |
| 2017-12-31 | $59.83 Million | $-12.95 Million | -0.216x | -27.23% |
| 2016-12-31 | $24.28 Million | $-4.13 Million | -0.170x | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more